Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

DA-125 [2-[(2R,4S)-4- [(2S,3R,4R,5S,6S)-3-fluoro- 4...

Synonyms: SureCN4849040, AC1L3FWQ, LS-16020, DA 125, 140637-82-7, ...

This record was replaced with 114759.

Roh, J.K. et al., Lee, S.D. et al., Park, H.J. et al., Kang, Y.K. et al., Kim, S.G. et al., et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 3-aminopropanoic acid [2-[(2S,4S)-4-[(2S,3R,4R,5R,6S)-3-fluoro-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] ester

Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases [1].
The dose of DA-125 was 80 mg/m(2 )during the first cycle, and was adjusted to between 60 and 100 mg/m(2) according to the observed toxicities during subsequent cycles [2].
A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer [2].
However, at DA-125 dose of 80 mg/m2, 1 out of 3 patients developed grade III leukopenia and grade IV neutropenia [3].
The main side-effects of DA-125 were nausea, vomiting, leukopenia (especially neutropenia), and thrombocytopenia [3].

High impact information on 3-aminopropanoic acid [2-[(2S,4S)-4-[(2S,3R,4R,5R,6S)-3-fluoro-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] ester

Gelatin zymography analysis also showed a significant down-regulation of MMP-2 and MMP-9 expression in HT1080 cells treated with DA-125 compared to controls [1].
Dose-dependent decreases of MMPs and TIMPs mRNA levels were observed in DA-125-treated HT1080 human fibrosarcoma cells detected by reverse transcriptase-polymerase chain reaction [1].
In addition, DA-125 inhibited the invasion, motility and cell migration, and colony formation of tumor cells [1].
Because activation of MAP kinases, in particular c-Jun N-terminal kinase (JNK), is implicated in apoptotic cell death, the signaling pathways responsible for DA-125-induced apoptosis were studied [4].
Apoptosis induced by DA-125 involved the pathway of JNK1, but not ERK1/2 or p38 kinase [4].

Chemical compound and disease context of 3-aminopropanoic acid [2-[(2S,4S)-4-[(2S,3R,4R,5R,6S)-3-fluoro-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] ester

PURPOSE: DA-125 is a novel anthracycline derivative developed by Dong-A Pharmaceutical Company, Korea. Preclinical studies have suggested that DA-125 has greater efficacy and less toxicity than doxorubicin [2].

Biological context of 3-aminopropanoic acid [2-[(2S,4S)-4-[(2S,3R,4R,5R,6S)-3-fluoro-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] ester

DA-125-induced apoptosis was also decreased in JNK1- -transfected cells [4].
In the MTT test, DA-125 showed lower IC50 values than doxorubicin for 14 of 20 cell lines [5].
Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats [6].
The tissue distribution, and biliary and urinary excretion of four metabolites (M1-M4) of a new anthracycline antineoplastic agent (DA-125) were compared after single and multiple (7 consecutive days) intravenous (i.v.) administration to rats [6].
DA-125 was given at dose levels of 0, 0.1, 0.3, and 1.0 mg/kg/day administered intravenously to pregnant rats from days 7 to 17 of gestation [7].

Anatomical context of 3-aminopropanoic acid [2-[(2S,4S)-4-[(2S,3R,4R,5R,6S)-3-fluoro-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] ester

Cellular uptake and antitumor activity of the new anthracycline analog DA-125 in human cancer cell lines [5].
The maximally tolerated dose (MTD) of DA-125 was determined to be 100 mg/m2, and the dose-limiting factor for DA-125 was bone marrow suppression [3].
Mean AUAts (area under the amount-time curves from time zero to last measurement time t) (or AUCts-area under the plasma concentration-time curves from time zero until the last measurement time t) of M1-M4 in each tissue after single and multiple administrations of DA-125 were also comparable except in the bone marrow and thymus [6].

Associations of 3-aminopropanoic acid [2-[(2S,4S)-4-[(2S,3R,4R,5R,6S)-3-fluoro-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] ester with other chemical compounds

Among cancer cells from the stomach and colon, DA-125 was more potent than doxorubicin in 12 of 14 cell lines [5].
The pharmacokinetics of M1, M2, M3 and/or M4 were compared after intravenous (i.v.) administration of DA-125 and/or ME2303 to mice (25 mg kg(-1)) and rats (5, 10, 20, 30, and 40 mg kg(-1)) [8].

Gene context of 3-aminopropanoic acid [2-[(2S,4S)-4-[(2S,3R,4R,5R,6S)-3-fluoro-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] ester

In all lines tested, the mean IC50 values for both DA-125 and ADM were lowest in the parent cells, followed by CDDP-resistant cells and ADM-resistant cells [9].

Analytical, diagnostic and therapeutic context of 3-aminopropanoic acid [2-[(2S,4S)-4-[(2S,3R,4R,5R,6S)-3-fluoro-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxo-ethyl] ester

Electrophoretic mobility shift assay demonstrated that DA-125 modulates the binding activity of NF-kappaB [1].
Between May 1996 and April 1997, 20 patients entered into this trial and were treated with DA-125 administered as a 5-min intravenous infusion every 3 weeks [2].
Simultaneous determination of a new anthracycline, DA-125, and its metabolites M1, M2, M3 and M4 in plasma and urine by high-performance liquid chromatography [10].
Single dose of DA-125, 20 (n = 3), 40 (n = 3), 60 (n = 3), 80 (n = 6), or 100 (n = 6) mg/m2 body surface area, was administered intravenously in 5 min to 21 patients with various types of cancer as phase I clinical trial [3].

References

Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. Park, H.J., Chung, H.J., Min, H.Y., Park, E.J., Hong, J.Y., Kim, W.B., Kim, S.H., Lee, S.K. Biochem. Pharmacol. (2005) [Pubmed]
A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer. Kang, Y.K., Ryoo, B.Y., Kim, T.Y., Im, Y.H., Kim, B.S., Park, Y.H., Lee, C.T. Cancer Chemother. Pharmacol. (1999) [Pubmed]
Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. Roh, J.K., Rha, S.Y., Lee, C.I., Lee, K.H., Lee, J.J., Shim, H.J., Lee, S.D., Kim, W.B., Yang, J., Kim, S.H., Lee, M.G. International journal of clinical pharmacology and therapeutics. (1998) [Pubmed]
DA-125, a novel anthracycline derivative showing high-affinity DNA binding and topoisomerase II inhibitory activities, exerts cytotoxicity via c-Jun N-terminal kinase pathway. Kim, S.G., Sung, M., Kang, K.W., Kim, S.H., Son, M.H., Kim, W.B. Cancer Chemother. Pharmacol. (2001) [Pubmed]
Cellular uptake and antitumor activity of the new anthracycline analog DA-125 in human cancer cell lines. Lim, K.H., Kim, H.S., Yang, Y.M., Lee, S.D., Kim, W.B., Yang, J., Park, J.G. Cancer Chemother. Pharmacol. (1997) [Pubmed]
Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. Lee, S.D., Lee, W.I., Shim, H.J., Lee, E.D., Kim, W.B., Yang, J., Kim, C.K., Lee, M.G. Journal of clinical pharmacy and therapeutics. (1996) [Pubmed]
Teratogenic effects of DA-125, a new anthracycline anticancer agent, in rats. Chung, M.K., Kim, J.C., Roh, J.K. Reprod. Toxicol. (1995) [Pubmed]
Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. Yoon, E.J., Lee, W.I., Shim, H.J., Lee, S.D., Kim, W.B., Yang, J., Lee, M.G. Biopharmaceutics & drug disposition. (1996) [Pubmed]
Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin. Hong, W.S., Jung, H.Y., Yang, S.K., Kim, H.R., Min, Y.I. Anticancer Res. (1997) [Pubmed]
Simultaneous determination of a new anthracycline, DA-125, and its metabolites M1, M2, M3 and M4 in plasma and urine by high-performance liquid chromatography. Shim, H.J., Lee, E.D., Yoon, E.J., Lee, S.D., Kim, W.B., Yang, J., Lee, M.G. J. Chromatogr. B, Biomed. Appl. (1994) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.